Guhan Pharmaceutical disclosed its earnings forecast, expecting a net loss attributable to the parent of 13 million to 18 million yuan in the first half of 2026, compared with a loss of 17.1701 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 15 million to 21 million yuan, compared with a loss of 22.6522 million yuan in the same period last year. The main reason for the loss is the impact of the centralized drug procurement policy, which has led to a continued decline in sales revenue of the core product Yixinshu Tablets of its wholly-owned subsidiary Guhan Guangdong Pharmaceutical Company Limited, resulting in an expanded loss for the subsidiary. In addition, in the same period last year, the company received a reversal of credit impairment losses of about 6 million yuan from the original shareholders' performance compensation, and there is no such income in this period.
Tus Pharmaceutical Group Co LtdCentralized drug procurement policy negatively impacts subsidiary's core product sales, affecting parent company's earnings.
Centralized drug procurement policy causes continued decline in sales revenue of core product Yixinshu Tablets, leading to expanded loss.